These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29088297)

  • 1. Questioning the role of selected somatic PIK3C2B mutations in squamous non-small cell lung cancer oncogenesis.
    Kind M; Klukowska-Rötzler J; Berezowska S; Arcaro A; Charles RP
    PLoS One; 2017; 12(10):e0187308. PubMed ID: 29088297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component.
    Pan Y; Wang R; Ye T; Li C; Hu H; Yu Y; Zhang Y; Wang L; Luo X; Li H; Li Y; Shen L; Sun Y; Chen H
    Chest; 2014 Mar; 145(3):473-479. PubMed ID: 24158231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies.
    Ho HL; Kao HL; Yeh YC; Chou TY
    Diagn Pathol; 2019 Jun; 14(1):59. PubMed ID: 31221183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
    Scheffler M; Bos M; Gardizi M; König K; Michels S; Fassunke J; Heydt C; Künstlinger H; Ihle M; Ueckeroth F; Albus K; Serke M; Gerigk U; Schulte W; Töpelt K; Nogova L; Zander T; Engel-Riedel W; Stoelben E; Ko YD; Randerath W; Kaminsky B; Panse J; Becker C; Hellmich M; Merkelbach-Bruse S; Heukamp LC; Büttner R; Wolf J
    Oncotarget; 2015 Jan; 6(2):1315-26. PubMed ID: 25473901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
    Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
    J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplatform-based molecular subtypes of non-small-cell lung cancer.
    Chen F; Zhang Y; Parra E; Rodriguez J; Behrens C; Akbani R; Lu Y; Kurie JM; Gibbons DL; Mills GB; Wistuba II; Creighton CJ
    Oncogene; 2017 Mar; 36(10):1384-1393. PubMed ID: 27775076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized therapy on the horizon for squamous cell carcinoma of the lung.
    Kim HS; Mitsudomi T; Soo RA; Cho BC
    Lung Cancer; 2013 Jun; 80(3):249-55. PubMed ID: 23489560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
    Wang L; Hu H; Pan Y; Wang R; Li Y; Shen L; Yu Y; Li H; Cai D; Sun Y; Chen H
    PLoS One; 2014; 9(2):e88291. PubMed ID: 24533074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development.
    Lockwood WW; Wilson IM; Coe BP; Chari R; Pikor LA; Thu KL; Solis LM; Nunez MI; Behrens C; Yee J; English J; Murray N; Tsao MS; Minna JD; Gazdar AF; Wistuba II; MacAulay CE; Lam S; Lam WL
    PLoS One; 2012; 7(5):e37775. PubMed ID: 22629454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein Tyrosine Phosphatase Non-Receptor 11 (
    Richards CE; Elamin YY; Carr A; Gately K; Rafee S; Cremona M; Hanrahan E; Smyth R; Ryan D; Morgan RK; Kennedy S; Hudson L; Fay J; O'Byrne K; Hennessy BT; Toomey S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445722
    [No Abstract]   [Full Text] [Related]  

  • 11. FGFR genes mutation is an independent prognostic factor and associated with lymph node metastasis in squamous non-small cell lung cancer.
    Li JJ; Yan S; Pan Y; Liu Z; Liu Y; Deng Q; Tan Q; Woodward ER; Wu N
    Cancer Biol Ther; 2018; 19(12):1108-1116. PubMed ID: 30403900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
    Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M
    Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort.
    Lim GHT; Balbi KJ; Poskitt B; Bennett P; Moore DA
    Lung Cancer; 2022 Nov; 173():71-74. PubMed ID: 36156323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.
    Pazarentzos E; Giannikopoulos P; Hrustanovic G; St John J; Olivas VR; Gubens MA; Balassanian R; Weissman J; Polkinghorn W; Bivona TG
    Oncogene; 2016 Mar; 35(9):1198-205. PubMed ID: 25982275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC).
    Ji M; Guan H; Gao C; Shi B; Hou P
    BMC Cancer; 2011 Apr; 11():147. PubMed ID: 21507233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Squamous Cell Lung Cancers from Appalachian Kentucky.
    Liu J; Murali T; Yu T; Liu C; Sivakumaran TA; Moseley HNB; Zhulin IB; Weiss HL; Durbin EB; Ellingson SR; Liu J; Huang B; Hallahan BJ; Horbinski CM; Hodges K; Napier DL; Bocklage T; Mueller J; Vanderford NL; Fardo DW; Wang C; Arnold SM
    Cancer Epidemiol Biomarkers Prev; 2019 Feb; 28(2):348-356. PubMed ID: 30377206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients.
    Glaser M; Rasokat A; Prang D; Nogova L; Wömpner C; Schmitz J; Bitter E; Terjung I; Eisert A; Fischer R; John F; von Levetzow C; Michels S; Riedel R; Ruge L; Scharpenseel H; Siebolts U; Merkelbach-Bruse S; Buettner R; Brägelmann J; Wolf J; Scheffler M
    Lung Cancer; 2023 Oct; 184():107344. PubMed ID: 37579577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
    Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B
    Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
    Wei XW; Gao X; Zhang XC; Yang JJ; Chen ZH; Wu YL; Zhou Q
    Thorac Cancer; 2020 Jun; 11(6):1512-1521. PubMed ID: 32291971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.